Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

6108 - Quality of life, late effects, and related clinical factors among Korean colorectal cancer survivors

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Ji Soo Park

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

J.S. Park1, T.I. Kim2

Author affiliations

  • 1 Cancer Prevention Center, Yonsei Cancer Center, Yonsei University, 120-752 - Seoul/KR
  • 2 Division Of Gastroenterology, Department Of Internal Medicine, Yonsei University College of Medicine, 03722 - Seoul/KR
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 6108

Background

Colorectal cancer (CRC) is one of the most common cancers worldwide, and the third most common cancer in Korea. Although the number of Korean CRC survivors is estimated over 220,000, we have insufficient survivorship care program to improve survival and quality of life (QoL) of CRC survivors.

Methods

We started to build a prospective cohort on October, 2016, and collected clinicopathological and social factors from 265 Korean CRC survivors in Cancer Prevention Center, Yonsei Cancer Center, Seoul, Republic of Korea. Health-related QoL (HRQOL) was assessed using EORTC-QLQ C30, CR29, ELD14, CIPN20, and EQ-VAS in 189 CRC survivors.

Results

Median duration of cancer survivorship was 70.7 months (range, 0.7-209.8), and 80 patients (42.3%) was long term CRC survivor (who live with cancer more than 5 years). In terms of HRQOL, median scale was 63.4 (standard deviation [SD], ±21.2) for global health, 81.7 (±15.3) for function, and 19.1 (±14.7) for symptom in all CRC survivors. Symptom scale was higher in the long-term survivors (21.8 vs. 17.1; P = 0.040), and in female patients (21.4 vs. 15.3; P = 0.006). Higher stage of disease (III or IV) was related to higher symptom scale (21.6 vs. 17.2; P = 0.042), and lower functional scale (78.2 vs. 84.3; P = 0.005). Frequently reported late effects were fatigue, insomnia, flatulence, bloated feeling, defecation problem, urinary frequency, sexual dysfunction in male, and sensory neuropathy. Insomnia (P = 0.018), sexual dysfunction in male (P = 0.003), and sensory neuropathy (P = 0.043) were significantly correlated with lower HRQOL scales. In the patients who were treated with oxaliplatin (n = 41), chemotherapy-induced neuropathy is related to worse global health (hazard ratio [HR], -3.29; 95% confidence interval [CI], -8.34- -2.0; P = 0.002).

Conclusions

Various late effects are found in CRC survivors, and late effects may worsen the HRQOL of Korean CRC survivors. We are developing personalized and integrative management programs for CRC survivors.

Clinical trial identification

Legal entity responsible for the study

Yonsei University College of Medicine, Ministry of Health & Welfare, Republic of Korea.

Funding

This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (1631020).

Editorial Acknowledgement

This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (1631020).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings